Clinical Trial Update: The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluates efficacy and tolerability of combining Faslodex (fulvestrant) and Aromasin (exemestane) in hormone receptor-positive, postmenopausal wom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Status: COMPLETED